Mercer Global Advisors
ANIK icon

Mercer Global Advisors’s Anika Therapeutics ANIK Stock Holding History

Mercer Global Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Buy
17,596
+4,851
+38% +$56.3K ﹤0.01% 2595
2025
Q4 		$122K Buy
+12,745
New +$122K ﹤0.01% 2678

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Mercer Global Advisors's ANIK Position: Q1 2026 in Review

Mercer Global Advisors increased its Anika Therapeutics (ANIK) stake by 38% in Q1 2026, buying an estimated $56.3K and bringing the position to 17,596 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #2595.

Mercer Global Advisors first reported a position in ANIK in Q4 2025 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Mercer Global Advisors held 17,596 shares of Anika Therapeutics worth $255K as of Q1 2026.
  • Mercer Global Advisors bought 4,851 Anika Therapeutics shares in Q1 2026, an estimated $56.3K.
  • Anika Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2595 holding.
  • Mercer Global Advisors first reported a position in Anika Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.